3 ASX All Ords health care shares that reached 52-week peaks today

These health care companies finished the week on a positive note.

| More on:
Two happy scientists analysing test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX All Ordinaries Index (ASX: XAO) closed down 0.68% to 8,416.60 points on Friday.

However, these three ASX All Ords health care shares stood out after hitting new 52-week highs.

3 ASX All Ords health care shares that hit new highs

Pro Medicus Limited (ASX: PME)

Pro Medicus shares hit a new all-time high of $181.28 despite no news from the company on Friday.

This ASX All Ords health care stock has ripped up the charts in 2024, with the share price up 86%.

According to a recent note from top broker Goldman Sachs, Pro Medicus has market leadership in health imaging and competitive advantages over its peers.

The company has reported plenty of new contracts this year. The broker says Pro Medicus has a 7% market share in the United States but expects this to grow to more than 25%.

The broker also cites a strong return on investment (ROI) for the Visage product and exciting prospects for growth due to artificial intelligence (AI).

Goldman has a buy rating on Pro Medicus with a 12-month share price target of $193.

The ASX All Ords healthcare share is up 117% over the past 12 months.

Mesoblast Ltd (ASX: MSB)

The Mesoblast share price reached a new 52-week peak of $1.54 despite no news from the company.

It's been a crazy week for this ASX biotech stock, with share price growth of almost 30% in just five days.

An announcement on Monday seems to be the catalyst for this growth, with no further news since.

Mesoblast announced it had entered into a convertible note subscription agreement with its largest shareholder, Gregory George.

The agreement stipulates that Mesoblast can issue up to US$50 million in convertible notes in US$10 million tranches over a 90-day period if the United States Food and Drug Administration (FDA) approves its lead drug candidate, remestemcel-L (brand name Ryoncil).

The convertible notes have a coupon of 5% per annum on the face value. The funding would enable Mesoblast to immediately launch its go-to-market commercial strategy after the approval.

Ryoncil treats steroid-refractory acute graft versus host disease (SR-aGvHD) in children. The FDA has previously rejected the drug and asked for more medical trials.

Mesoblast resubmitted the drug for consideration in July and expects a decision by 7 January 2025.

The ASX 300 biotech share is up 314% over the past 12 months.

Opthea Ltd (ASX: OPT)

This ASX All Ords health care stock touched a new 52-week high of 87 cents on Friday.

This clinical-stage biopharmaceutical company is focused on developing treatments for common and progressive eye diseases.

These include wet age-related macular degeneration (wet AMD), one of the leading causes of blindness in older adults, and diabetic macular edema (DME).

Opthea's lead product, sozinibercept, is being evaluated in two phase 3 clinical trials. It is being used in combination with standard-of-care anti-VEGF-A monotherapies to see if it achieves better results for patients.

The company anticipates top-line readouts in early 2Q CY25 (COAST trial) and mid-CY25 (SHORE trial). If successful, Opthea hopes to apply for FDA approval.

The company did not issue any price-sensitive news today.

The ASX All Ords health care share has risen by 166% over the past 12 months.

Should you invest $1,000 in Mesoblast Limited right now?

Before you buy Mesoblast Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mesoblast Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Bronwyn Allen has positions in Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on 52-Week Highs

Hands reaching high for a trophy with a sunset in the background.
52-Week Highs

These 7 ASX 200 shares just hit new 52-week highs

Do you own any of these winners today?

Read more »

Teen standing in a city street smiling and throwing sparkling gold glitter into the air.
52-Week Highs

11 ASX 200 stocks streaking to multi-year highs today

The benchmark ASX 200 is in the green and these 11 stocks are setting new price records.

Read more »

Man with rocket wings which have flames coming out of them.
52-Week Highs

5 ASX 200 stocks leaping to 52+-week highs in Monday's sinking market

Investors just sent these ASX 200 stocks to new one-year-plus highs. Let’s find out why.

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
52-Week Highs

Big ASX news: 10 ASX 200 shares hit new 52-week highs today

Do you own any of these lucky stocks?

Read more »

A beautiful ocean vista is shown with a woman whose back is to the camera holding her arms up in triumph as she stands at the top of a rock feeling thrilled that ASX 200 shares are reaching multi-year high prices today
Bank Shares

Big ASX news: NAB shares hit 18-year high

The last time NAB shares were at this level was in November 2007.

Read more »

Multiracial happy young people stacking hands outside - University students hugging in college campus - Youth community concept with guys and girls standing together supporting each other.
52-Week Highs

These 11 ASX 200 shares are hitting new 52-week highs today

These shares are on form and hitting new highs today. Let's find out what is happening.

Read more »

Earnings Results

This $27 billion ASX 200 share is jumping on strong quarterly results

Investors are cheering on this giant's quarterly update this morning.

Read more »

Hiker man backpacker with hands up in the summer mountains with cloudy sky.
52-Week Highs

These 10 ASX 200 shares just hit new 52-week highs

Do you own any of these ASX high-flyers?

Read more »